No Data
List of cloud-breaking stocks [Ichimoku Kinko Hyo - List of cloud-breaking stocks]
○ List of stocks breaking through the cloud Market Code Stock Name Closing Price Leading Span A Leading Span B Main Board ＜1417＞ Miraitowan 2275 2257.25 2229 ＜2170＞ LINK & M 5825 68.55 71 ＜2307＞ Crosscat 1208 1047 1093 ＜3191＞ JOYY Inc. American Depositary Shares 1921 1835.75 1910 ＜3397＞ Toridoll 3832 3779.53
Takeda Secures EMA Approval for Additional Injection Option for Hereditary Angioedema Drug
La Agencia Europea De Medicamentos Aprueba Una Opción Adicional De Administración Subcutánea De TAKHZYRO
The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO (Lanadelumab) for Patients Aged 12 Years and Above With Recurrent Attacks of Hereditary Angioedema (HAE)
Trump Tells Big Pharma to Bring Production Home or Face Tariffs: Bloomberg News
Noil Immune --- For the fiscal year ending December 2024, the in-house drug development business and the joint pipeline will continue to be promoted.
Noil Immune Biotech <4893> announced its financial results for the fiscal year ending December 2024 on the 14th. Business revenue was 0.007 billion yen (compared to 0.316 billion yen in the previous term), operating loss was 1.069 billion yen (compared to a loss of 0.775 billion yen in the previous term), recurring loss was 0.962 billion yen (compared to a loss of 1.127 billion yen in the previous term), and net loss for the year was 0.964 billion yen (compared to a loss of 1.13 billion yen in the previous term). As for the company's business status for the fiscal year, the self-developed drug discovery business based on PRIME technology and the joint pipeline will continue.
